ESOMEPRAZOLE MAGNESIUM; NAPROXEN: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ajanta Pharma Ltd	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	213699	ANDA	Ajanta Pharma USA Inc.	27241-202-60	60 TABLET, DELAYED RELEASE in 1 BOTTLE (27241-202-60)	2022-10-06
Ajanta Pharma Ltd	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	213699	ANDA	Ajanta Pharma USA Inc.	27241-203-60	60 TABLET, DELAYED RELEASE in 1 BOTTLE (27241-203-60)	2022-10-06
Ajanta Pharma Ltd	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	213699	ANDA	Bryant Ranch Prepack	63629-4873-1	60 TABLET, DELAYED RELEASE in 1 BOTTLE (63629-4873-1)	2022-10-06
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Major Suppliers for Esomeprazole Magnesium; Naproxen Active Pharmaceutical Ingredients (APIs)

The supply chain for Esomeprazole Magnesium; Naproxen, a fixed-dose combination drug, involves multiple stakeholders, primarily API manufacturers. Key global API suppliers for esomeprazole magnesium and naproxen include companies based in India and China, leveraging established chemical synthesis capabilities and cost efficiencies. Availability and pricing are subject to regulatory approvals, manufacturing capacity, and raw material sourcing.

Esomeprazole Magnesium API Suppliers

Esomeprazole magnesium is the S-enantiomer of omeprazole, a proton pump inhibitor. Its synthesis requires chiral resolution or asymmetric synthesis to achieve high enantiomeric purity.

Aurobindo Pharma Ltd. (India): A significant player in generic API manufacturing, Aurobindo offers a broad portfolio, including proton pump inhibitors. Their manufacturing facilities are approved by major regulatory bodies such as the US FDA and EMA.
Dr. Reddy's Laboratories (India): Dr. Reddy's is a vertically integrated pharmaceutical company with strong API development and manufacturing capabilities. They supply APIs for various therapeutic areas, including gastrointestinal drugs.
Divi's Laboratories (India): Divi's is a leading custom synthesis and contract manufacturing organization (CMO) for APIs. They are known for their large-scale manufacturing capacity and adherence to stringent quality standards.
Lupin Ltd. (India): Lupin is another major Indian pharmaceutical company with extensive API production facilities. They are a key supplier of APIs for both regulated and emerging markets.
Zhejiang NHU Co., Ltd. (China): NHU is a prominent Chinese pharmaceutical and chemical manufacturer. They have a significant presence in the vitamin and API markets, including esomeprazole.

Naproxen API Suppliers

Naproxen is a nonsteroidal anti-inflammatory drug (NSAID). Its synthesis typically involves multi-step chemical processes.

Albemarle Corporation (USA): While Albemarle has a diverse chemical portfolio, it has been a notable supplier of NSAID intermediates and APIs.
Anqiu Hongda Pharmaceutical Co., Ltd. (China): This Chinese company is a producer of various APIs, including naproxen, serving global pharmaceutical markets.
Atul Ltd. (India): Atul is a diversified chemical conglomerate with a strong presence in the pharmaceutical intermediates and API sector, including naproxen.
Granules India Ltd. (India): Granules India specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). They are a significant producer of ibuprofen and naproxen.
Mallinckrodt Pharmaceuticals (Ireland): Mallinckrodt is a global manufacturer of specialty pharmaceutical products and active pharmaceutical ingredients. They have historically supplied naproxen API.
Solvay S.A. (Belgium): Solvay is a global chemical company that has been involved in the production of pharmaceutical ingredients, including those for NSAIDs.

Key Considerations for Esomeprazole Magnesium; Naproxen Sourcing

When selecting suppliers for Esomeprazole Magnesium; Naproxen, pharmaceutical companies must evaluate several critical factors to ensure product quality, regulatory compliance, and supply chain security.

Regulatory Compliance and Quality Standards

Good Manufacturing Practices (GMP): All API suppliers must adhere to current GMP guidelines as mandated by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national bodies.
Drug Master Files (DMFs): Suppliers should have comprehensive DMFs filed with regulatory agencies. These documents contain detailed information about the manufacturing process, quality control, and stability of the API.
Audits and Inspections: Pharmaceutical companies conduct rigorous audits of their suppliers' manufacturing sites to verify compliance with quality standards and regulatory requirements. Successful FDA or EMA inspections are critical.
Certificates of Analysis (CoA): Each batch of API must be accompanied by a CoA, detailing its specifications, test results, and conformity to pharmacopoeial standards (e.g., USP, EP).
Impurity Profiles: Control over impurities, including residual solvents, heavy metals, and process-related impurities, is paramount. The enantiomeric purity of esomeprazole magnesium is a specific concern.

Manufacturing Capacity and Lead Times

Scalability: Suppliers must demonstrate the capacity to produce sufficient quantities of APIs to meet market demand, including potential surges.
Reliability: Consistent production and on-time delivery are essential to avoid drug shortages and maintain market presence. Lead times for API production and delivery can range from several weeks to months.
Contingency Planning: Pharmaceutical companies often qualify multiple suppliers to mitigate risks associated with single-source dependencies, geopolitical instability, or manufacturing disruptions.

Cost and Economic Factors

Pricing: API costs are a significant component of drug manufacturing expenses. Competitive pricing from suppliers is a key consideration.
Raw Material Sourcing: The cost and availability of key starting materials and intermediates can impact API pricing and supply stability. Suppliers with robust backward integration into raw material production may offer advantages.
Currency Fluctuations: For global sourcing, currency exchange rates can affect the landed cost of APIs.

Intellectual Property (IP) and Patent Landscape

Freedom to Operate (FTO): Pharmaceutical companies must ensure that their chosen API suppliers are not infringing on existing patents related to the synthesis processes or the APIs themselves. This requires thorough IP due diligence.
Patent Expiry: The patent status of the Esomeprazole Magnesium; Naproxen combination drug and its individual components influences market competition and the ability of generic manufacturers to enter the market.
Process Patents: Companies may develop novel or improved synthesis routes for APIs. The patentability of these processes can create competitive advantages or licensing opportunities.

Global API Manufacturing Hubs and Trends

The global landscape for API manufacturing is dominated by a few key regions.

India

India is a leading global supplier of generic APIs, including those for gastrointestinal drugs and NSAIDs. Factors contributing to its prominence include:

Skilled Workforce: A large pool of experienced chemists and engineers.
Cost Advantages: Lower labor and operational costs compared to Western countries.
Regulatory Acumen: Significant investment in compliance with international regulatory standards, leading to numerous FDA and EMA-approved facilities.
Government Support: Policy initiatives promoting the pharmaceutical sector.

China

China is another major producer of APIs, known for its large-scale chemical manufacturing capabilities and competitive pricing.

Scale of Production: Extensive chemical infrastructure and production capacity.
Cost Competitiveness: Generally lower manufacturing costs.
Regulatory Evolution: Increasing focus on quality and environmental standards in recent years.

Western Markets (USA, Europe)

While manufacturing has largely shifted to Asia, some specialized API manufacturing remains in Western countries, often focusing on:

Complex Synthesis: APIs requiring highly specialized or proprietary synthesis technologies.
High-Value Products: Drugs with smaller market volumes or those requiring exceptionally stringent quality control.
Reshoring Initiatives: Growing interest in diversifying supply chains and bringing some manufacturing back to domestic markets due to geopolitical concerns and supply chain vulnerabilities.

Competitive Landscape for Esomeprazole Magnesium; Naproxen Generics

The market for Esomeprazole Magnesium; Naproxen is characterized by competition from both branded and generic manufacturers. The patent expiry of key proton pump inhibitors and NSAIDs has opened doors for generic entry.

Branded Product: The original branded combination product (e.g., Vimovo) faces competition from generic versions once its market exclusivity periods expire.
Generic Manufacturers: Companies specializing in generic drug development and manufacturing are key players. They rely on sourcing high-quality, cost-effective APIs from reputable suppliers.
Contract Manufacturing Organizations (CMOs): CMOs play a crucial role in both API synthesis and the manufacturing of finished dosage forms, providing services to smaller pharmaceutical companies or those looking to outsource production.

Supply Chain Risks and Mitigation Strategies

The pharmaceutical supply chain for Esomeprazole Magnesium; Naproxen is susceptible to various risks.

Geopolitical Instability and Trade Policies

Impact: Trade wars, tariffs, and political tensions can disrupt the flow of APIs and raw materials between countries.
Mitigation: Diversify supplier base across different geopolitical regions. Monitor trade policies and regulatory changes.

Quality Control Failures and Recalls

Impact: Substandard APIs can lead to product recalls, regulatory sanctions, and significant reputational damage.
Mitigation: Implement robust supplier qualification and ongoing monitoring programs. Conduct regular audits and quality testing.

Raw Material Shortages

Impact: Disruptions in the supply of essential chemical precursors can halt API production.
Mitigation: Secure multiple sources for critical raw materials. Maintain safety stock. Explore vertical integration or long-term supply agreements.

Natural Disasters and Pandemics

Impact: Events like pandemics (e.g., COVID-19) or natural disasters can severely disrupt manufacturing operations and global logistics.
Mitigation: Develop business continuity plans. Increase inventory levels for critical supplies. Utilize diversified logistics providers.

Regulatory Changes

Impact: Evolving regulatory requirements in different markets can necessitate changes in manufacturing processes or quality standards.
Mitigation: Stay abreast of regulatory updates from key health authorities. Ensure suppliers have the flexibility to adapt to new requirements.

Key Takeaways

The supply chain for Esomeprazole Magnesium; Naproxen APIs is concentrated among manufacturers in India and China, known for their cost competitiveness and established manufacturing infrastructure. Sourcing decisions must prioritize regulatory compliance, quality standards, and reliable supply. Key considerations include GMP adherence, DMF filings, supplier audits, and impurity profiling. Intellectual property protection and freedom-to-operate assessments are critical for market entry and competition. Pharmaceutical companies must implement robust risk mitigation strategies to address potential disruptions from geopolitical instability, quality failures, raw material shortages, and global health crises.

FAQs

What are the primary regions for manufacturing Esomeprazole Magnesium and Naproxen APIs?

The primary manufacturing regions for Esomeprazole Magnesium and Naproxen APIs are India and China, due to their established chemical synthesis capabilities and competitive cost structures.

How is the regulatory compliance of API suppliers typically verified?

Regulatory compliance is verified through stringent supplier qualification processes, which include on-site audits, review of Drug Master Files (DMFs), assessment of Good Manufacturing Practices (GMP) adherence, and examination of successful regulatory inspections by bodies like the FDA and EMA.

What are the main risks associated with sourcing APIs from a single supplier?

Sourcing APIs from a single supplier creates significant risks, including disruptions due to manufacturing issues, quality control failures, geopolitical instability, or natural disasters. This single point of failure can lead to drug shortages and market supply interruptions.

How do patent expiries affect the API sourcing strategy for Esomeprazole Magnesium; Naproxen?

Patent expiries of branded Esomeprazole Magnesium; Naproxen products or their key components typically lead to increased demand for generic APIs. This allows generic manufacturers to enter the market, intensifying competition among API suppliers and potentially leading to price reductions.

What is the significance of Drug Master Files (DMFs) in the pharmaceutical supply chain?

Drug Master Files (DMFs) are critical documents submitted to regulatory agencies (like the FDA) that contain confidential, detailed information about the manufacturing, processing, packaging, and storing of an API. They allow regulatory bodies to review API quality and manufacturing practices without revealing proprietary information to the drug product manufacturer.

Suppliers and packagers for generic pharmaceutical drug: ESOMEPRAZOLE MAGNESIUM; NAPROXEN